Elicio Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Elicio Therapeutics Current Ratio Growth & History (ELTX)
Elicio Therapeutics's current ratio was 2.38 for fiscal 2025.
View full Elicio Therapeutics company overviewElicio Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.38 | 0.59 | +32.59% |
| 2024 | 2024-12-31 | 1.80 | 0.12 | +7.16% |
| 2023 | 2023-12-31 | 1.68 | 0.12 | +7.40% |
| 2022 | 2022-12-31 | 1.56 | −6.52 | −80.68% |
| 2021 | 2021-12-31 | 8.08 | 7.68 | +1952.04% |
| 2020 | 2020-12-31 | 0.39 | — | — |
Elicio Therapeutics quarterly current ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.77 | 0.49 | +21.61% |
| Q1 2026 | 2026-03-31 | 2.24 | 0.41 | +22.17% |
| Q4 2025 | 2025-12-31 | 2.38 | 0.59 | +32.59% |
| Q3 2025 | 2025-09-30 | 3.29 | −0.10 | −3.03% |
| Q2 2025 | 2025-06-30 | 2.28 | 1.40 | +158.24% |
| Q1 2025 | 2025-03-31 | 1.83 | −0.54 | −22.75% |
| Q4 2024 | 2024-12-31 | 1.80 | 0.12 | +7.16% |
| Q3 2024 | 2024-09-30 | 3.40 | 1.66 | +95.80% |
| Q2 2024 | 2024-06-30 | 0.88 | −2.57 | −74.45% |
| Q1 2024 | 2024-03-31 | 2.37 | −17.63 | −88.13% |
| Q4 2023 | 2023-12-31 | 1.68 | 0.12 | +7.40% |
| Q3 2023 | 2023-09-30 | 1.74 | −5.19 | −74.95% |
| Q2 2023 | 2023-06-30 | 3.45 | −5.02 | −59.24% |
| Q1 2023 | 2023-03-31 | 20.00 | 12.66 | +172.37% |
| Q4 2022 | 2022-12-31 | 1.56 | −6.52 | −80.68% |
| Q3 2022 | 2022-09-30 | 6.93 | 1.11 | +19.09% |
| Q2 2022 | 2022-06-30 | 8.47 | 2.64 | +45.20% |
| Q1 2022 | 2022-03-31 | 7.34 | −0.53 | −6.68% |
| Q4 2021 | 2021-12-31 | 8.08 | 7.68 | +1952.04% |
| Q3 2021 | 2021-09-30 | 5.82 | — | — |
| Q2 2021 | 2021-06-30 | 5.83 | — | — |
| Q1 2021 | 2021-03-31 | 7.87 | — | — |
| Q4 2020 | 2020-12-31 | 0.39 | — | — |
Elicio Therapeutics current ratio trends
Over the last five fiscal years, Elicio Therapeutics's current ratio increased from 0.39 to 2.38, a change of 1.99. The latest reported quarter, Q2 2026, shows 2.77.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Elicio Therapeutics source filings ↗